Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 50 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $1.725 million which missed the analyst consensus estimate of $3.602 million by 52.11 percent. This is a 14.85 percent increase over sales of $1.502 million the same period last year.